Arm A | Arm B | Arm C | |||||||
---|---|---|---|---|---|---|---|---|---|
Motesanib 125 mg QD | Motesanib 75 mg BID | Motesanib 75 mg BID | |||||||
2 wk on/1 wk off | 5 d on/2 d off | ||||||||
Patient incidence, n (%) | Baseline | Post baseline* | Post treatment† | Baseline | Post baseline* | Post treatment† | Baseline | Post baseline* | Post treatment† |
(n = 23) | (n = 23) | (n = 16) | (n = 11) | (n = 11) | (n = 9) | (n = 11) | (n = 11) | (n = 8) | |
Gallstones | 3 (13) | 4 (17) | 3 (19) | 3 (27) | 2 (18) | 2 (22) | 0 (0) | 0 (0) | 0 (0) |
Sludge | 0 (0) | 9 (39) | 4 (25) | 0 (0) | 4 (36) | 4 (44) | 0 (0) | 3 (27) | 0 (0) |
Pericholecystic fluid | 0 (0) | 1 (4) | 0 (0) | 1 (9) | 1 (9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Common duct dilation | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |